Antiangiogenic therapies in glioblastoma multiforme

References

• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science284(5422), 1994–1998 (1999).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD 2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg.175(3), 409–416 (1972).
   PubMed Web of Science ®Google Scholar
• Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat. Rev. Neurosci.8(8), 610–622 (2007).
   PubMed Web of Science ®Google Scholar
• Keunen O, Johansson M, Oudin A et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA108(9), 3749–3754 (2011).
   PubMed Web of Science ®Google Scholar
• Hattingen E, Jurcoane A, Bahr O et al. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol.13(12), 1349–1363 (2011).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanisation of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57(20), 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Moen MD. Bevacizumab: in previously treated glioblastoma. Drugs70(2), 181–189 (2010).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters KB et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J. Neurooncol.107(1), 155–164 (2012).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol.12(12), 1300–1310 (2010).
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, NGHiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol.29(2), 142–148 (2011).
   PubMed Web of Science ®Google Scholar
• Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther.28(4), 334–340 (2011).
   PubMed Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.75(1), 156–163 (2009).
   PubMed Web of Science ®Google Scholar
• Scott BJ, Quant EC, McNamara MB, Ryq PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neurooncol.12(6), 603–607 (2010).
   Google Scholar
• Gomez-Manzano C, Holash J, Fueyo J et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro. Oncol.10(6), 940–945 (2008).
   PubMed Web of Science ®Google Scholar
• deGroot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol.29(19), 2689–2695 (2011).
   Google Scholar
• Wachsberger PR, Burd R, Cardi C et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int. J. Radiat. Oncol. Biol. Phys.67(5), 1526–1537 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Ways DK et al. Protein kinase c lies on the signalling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res.59(17), 4413–4418 (1999).
   PubMed Web of Science ®Google Scholar
• Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell95(1), 29–39 (1998).
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCL), suppresses signalling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res.65(16), 7462–7469 (2005).
   PubMed Web of Science ®Google Scholar
• Fine HA, Kim L, Royce C. Results from Phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J. Clin. Oncol.23(Suppl.), 115S (2005) (Abstract 1504).
   Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of Enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol.28(7), 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Butowski N, Chang SM, Lamborn KR et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol.13(12), 1331–1338 (2011).
   PubMed Web of Science ®Google Scholar
• Kamoun WS, Ley CD, Farrar CT et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol.27(15), 2542–2552 (2009).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol.28(17), 2817–2823 (2010).
   PubMed Web of Science ®Google Scholar
• Mulholland P, Batchelor TT, Neyns B. A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Proc. ESMO Ann. Oncol.21, LBA7 (2010).
   Google Scholar
• Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol.12(8), 855–861 (2010).
   PubMedGoogle Scholar
• Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci. Lett.478(3), 165–170 (2010).
   PubMed Web of Science ®Google Scholar
• Yang F, Brown C, Buettner R et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther.9(4), 953–962 (2010).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Ervin T, Friedman E et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer116(15), 3663–3669 (2010).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Vredenburgh JJ, Coan A et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J. Neurooncol.105(3), 621–627 (2011).
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res.62(24), 7284–7290 (2002).
   PubMed Web of Science ®Google Scholar
• Wibom C, Sandstrom M, Henriksson R, Antti H, Johansson M, Bergenheim AT. Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model. Int. J. Oncol.37(4), 879–890 (2010).
   Google Scholar
• Drappatz J, Norden AD, Wong ET et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys.78(1), 85–90 (2010).
   PubMedGoogle Scholar
• Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients with progressive glioblastoma (GB). J. Clin. Oncol.28(15), 181S (2010) (Abstract 2006).
   PubMed Web of Science ®Google Scholar
• Du J, Bernasconi P, Clauser KR et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol.27(1), 77–83 (2009).
   PubMed Web of Science ®Google Scholar
• Milano V, Piao Y, LaFortune T, deGroot J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol. Cancer Ther.8(2), 394–406 (2009).
   PubMed Web of Science ®Google Scholar
• Premkumar DR, Jane EP, Pollack IF. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. Int. J. Oncol.37(3), 633–643 (2010).
   Google Scholar
• Lu-Emerson C, Norden AD, Drappatz J et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J. Neurooncol.104(1), 287–291 (2011).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Egorin MJ, Desjardins A et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer115(10), 2188–2198 (2009).
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Eichler AF, Plotkin SR et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol.103(2), 325–332 (2011).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Stupp R, Hau P et al. EORTC study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur. J. Cancer46(2), 348–354 (2010).
   PubMed Web of Science ®Google Scholar
• Tucker GC. Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep.8(2), 96–103 (2006).
   PubMedGoogle Scholar
• Maurer GD, Tritschlet I, Adams B et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro. Oncol.11(6), 747–756 (2009).
   PubMed Web of Science ®Google Scholar
• Mikkelsen T, Brodie C, Finniss S et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int. J. Cancer.124(11), 2719–2727 (2009).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol.28(16), 2712–2718 (2010).
   PubMed Web of Science ®Google Scholar
• Nabors LB, Fink K, Reardon DA et al. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: protocol of a multicenter, randomized, open-label, controlled Phase II study. J. Clin. Oncol.28(Suppl.), 15S (2010) (Abstract TPS151).
   Google Scholar
• Stupp R, Van Den Bent MJ, Erridge SC et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled Phase III trial (CENTRIC). J. Clin. Oncol.28(Suppl.), 15S (2010) (Abstract TPS152).
   PubMed Web of Science ®Google Scholar
• Son MJ, Kim JS, Kim MH. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. Int. J. Oncol.28(1), 53–59 (2006).
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Giglio P, Groves MD et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol.10(2), 216–222 (2008).
   PubMed Web of Science ®Google Scholar
• Fadul CE, Kingman LS, Meyer LP et al. A Phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J. Neurooncol.90(2), 229–235 (2008).
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Gonzalez J, Hunter K et al. A Phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol.12(11), 1167–1117 (2010).
   Google Scholar
• Drappatz J, Wong ET, Schiff D. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.73(1), 222–227 (2009).
   PubMed Web of Science ®Google Scholar
• Nabors LB, Fiveash JB, Markert JM et al. A Phase I trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch. Neurol.67(3), 313–319 (2010).
   PubMedGoogle Scholar
• Jun HT, Sun J, Rex K et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin. Cancer Res.13(22 Pt 1), 6735–6742 (2007).
   PubMed Web of Science ®Google Scholar
• Wen PY, Schiff D, Cloughesy TF et al. A Phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol.13(4), 437–446 (2011).
   PubMed Web of Science ®Google Scholar
• Mamluk R, Carvajal IM, Morse BA et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs2(2), 199–208 (2010).
   PubMed Web of Science ®Google Scholar
• Bhide RS, Lombardo LJ, Hunt JT et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer. Ther.9(2), 369–378 (2010).
   PubMed Web of Science ®Google Scholar
• Ranza E, Mazzini G, Facoetti A, Nano R. In vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J. Neurooncol.96(3), 349–357 (2010).
   Google Scholar
• Dresemann G, Weller M, Rosenthal MA et al. Imatinib in combination with hydoxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol.96(3), 393–402 (2010).
   PubMed Web of Science ®Google Scholar
• Dong Y, Jia L, Wang X et al. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signalling in malignant glioma cells. Int. J. Oncol.38(2), 555–569 (2011).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Paz K. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs11(1), 46–56 (2008).
   Google Scholar
• Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA. Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome. Neurology76(3), 236–241 (2011).
   PubMed Web of Science ®Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol.6(8), 465–477 (2009).
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol.23(15), 3502–3508 (2005).
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol.91(3), 329–336 (2009).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins JE, Herndon II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonalds criteria. J. Clin. Oncol.27(18), 2905–2908 (2009).
   PubMed Web of Science ®Google Scholar
• Wen P, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuroncology working group. J. Clin. Oncol.28(11), 1963–1972 (2010).
   PubMed Web of Science ®Google Scholar
• Quant EC, Norden AD, Drappatz, J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol.11(5), 550–555 (2009).
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell15(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M et al. Anti PlGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels. Cell131(3), 463–475 (2007).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Investigation.111(9), 1287–1295 (2003).
   PubMed Web of Science ®Google Scholar
• diTomaso E, Snuderl M, Kamoun WS et al. Glioblastoma recurrence after cediranib therapy in patients: lack of ‘rebound’ revascularization as mode of escape. Cancer Res.71(1), 19–28 (2011).
   Google Scholar
• Relf M, LeJeunes S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res.57(5), 963–969 (1997).
   PubMed Web of Science ®Google Scholar
• Sofuni A, Iijima H, Moriyasu F et al. Differnetial diagnosis of pancreatic tumors using ultrasound contrast imaging. J. Gastroenterol.40(5), 518–525 (2005).
   PubMedGoogle Scholar
• Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol.5(7), 378–391 (2008).
   PubMedGoogle Scholar
• Horn L, Dahlberg SE, Sandler AB et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J. Clin. Oncol.27(35), 6006–6011 (2009).
   PubMed Web of Science ®Google Scholar
• Greenfield JP, Jin DK, Young LM et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery64(5), 819–826 (2009).
   PubMedGoogle Scholar
• Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res.70(3), 1063–1071 (2010).
   PubMed Web of Science ®Google Scholar
• Xu L, Duda DG, di Tomaso E et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res.69(20), 7905–7910 (2009).
   PubMed Web of Science ®Google Scholar
• Saidi A, Hagedorn M, Allain N et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int. J. Cancer.125(5), 1054–1064 (2009).
   Google Scholar
• Wang SD, Rath P, Lal B et al. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene doi:10.1038/onc.2012.16 (2012) (Epub ahead of print).
   Google Scholar
• Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol.26(28), 4672–4678 (2008).
   PubMed Web of Science ®Google Scholar
• Hansen TF, Christensen RD, Andersen RF, Spindler KL, Johnsson A, Jakobsen A. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int. J. Colorectal Dis. doi:10.1007/s00384-011-1382-6 (2011) (Epub ahead of print).
   Google Scholar
• Murat A, Migliavacca E, Gorlia T et al. Stem cell-related self renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol.26(18), 3015–3024 (2008).
   PubMed Web of Science ®Google Scholar